Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

LabRoots Announces Comprehensive Agenda for its 4th Annual Drug Discovery & Development Online Virtual Event, hosted on February 24, 2021
  • USA - English

Watch presentations from leading academia and industry experts including Moderna and Pfizer, and much more!


News provided by

LabRoots

Feb 18, 2021, 10:00 ET

Share this article

Share toX

Share this article

Share toX

YORBA LINDA, Calif., Feb. 18, 2021 /PRNewswire-PRWeb/ -- LabRoots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is delighted to announce an invaluable forum for interdisciplinary exchange at the forefront of innovative technologies, and novel diagnostics and therapeutics in drug research during its free Drug Discovery & Development Virtual Event, scheduled February 24th.

Drug Discovery & Development 2021 provides leading academia and industry experts, research scholars, clinicians, laboratory managers and medical professionals the opportunity to share their research findings about all aspects of new practices in early phase drug discovery, novel advancements to clinical development, modern approaches to discovery, preclinical and clinical lab operations in COVID-19 Age, and biomarkers in drug development. The jam-packed agenda delivers informational presentations enabling participants to grasp the latest developments in different areas of drug discovery and clinical research, while serving as a catalyst to improve the understanding and advancements in such an ever-changing field.

This year's event will highlight two keynote deliveries, kicking off the one-day program with a discussion on "The biomarker to companion diagnostic continuum: a road map for the delivery of precision medicine," exploring key factors in the development of biomarker assays and requirements for transition to companion diagnostic applications, presented by Steven M. Anderson, PhD, Chief Scientific Officer at Covance Drug Development.

"The promise of precision medicine has currently been demonstrated in Oncology with many examples of novel targeted and immuno-oncology therapies and associated diagnostics," commented, Dr. Steven M. Anderson, Chief Scientific Officer, Covance Drug Development. "As a better understanding of the biology of cancer and other disease states increases, the opportunities for precision medicine will grow. Much of this understanding will be driven by developing diagnostic technologies and biomarker discovery and validation. Expansion of precision medicine has also been supported by new therapeutic approaches such as gene replacement therapy for rare diseases and adoptive cell therapies for in cancer. We are at an important inflection point for the delivery of precision medicine with the convergence of new therapeutic approaches and diagnostic technologies, all of which will provide significant benefit for patients," Anderson added.

Next, a keynote panel presentation will be shared titled, "Biomarker assays – bioanalytical meets CLIA," by both Andrew Roche, PhD, Senior Director, Scientific Affairs and Roger Hayes, PhD, Vice President, Bioanalytical Services, at ICON Laboratory Services to provide guidance on how to identify the most effective biomarkers, and discuss what level of validation is required to measure a biomarker?

Following in the afternoon session, attendees will be able to identify some of the challenges to screening G protein-coupled receptors (GPCRs) and describe some of the emerging technologies being used during a roundtable panel presentation named, "Recent trends in screening GPCR's."

Annette Gilchrist, Planning Committee Chairman and Associate Professor, Pharmaceutical Sciences, Midwestern University said, "I am honored to moderate a panel of renowned scientists representing both industry and academia who are working on G protein coupled receptors (GPCRs) for the LabRoots Drug Discovery Virtual Event.

"GPCRs are an important family of receptors, involved in the physiology and pathophysiology of many diverse diseases. Understanding their pharmacology continues to engage scientists globally, and diverse technologies are used to identify novel ligands for GPCRs. With a focus on recent trends in screening GPCRs, we will discuss some of the methods employed when using phenotypic assay, specifically the use of cellular thermal shift assays and mass spectrometry for target deconvolution. We will share methods being used to screen for ligands that target GPCR oligomers such as bioluminescence resonance energy transfer (BRET). The advancements in GPCR structures and emerging role of GPCRs in cancer will also be explored," added Gilchrist.

This premier event highlights outstanding preclinical drug discovery and new progress in drug research and pharmaceutical sciences via scheduled and on-demand lectures by renowned speakers, on stable cell line catalog products for drug discovery, COVID's impact on life sciences recruiting, evolution of a platform-based non-clinical safety assessment approach for vaccines, non-clinical COVID-19 vaccine development during a pandemic, the comprehensive A.I.-driven genomic landscape for ALS, to name a few.

"We are thrilled to maintain our commitment of sharing unique insights, revolutionary research, and critical advancements to the scientific community via our virtual educational platform," said Greg Cruikshank, Chief Executive Officer of LabRoots. "This year, our annual Drug Discovery & Development event will continue the tradition of the successful conferences from previous years showcasing scientific discoveries, cutting-edge advances and innovative approaches by world leaders in their respective fields to improve drug discovery going forward."

Produced on LabRoots' robust platform, while connecting across all desktop and mobile devices, the interactive environment offers one-stop collaboration complete with a lobby, auditorium, exhibit hall (driving innovations and highlighting the latest products and technologies), poster hall, and a networking lounge providing an enriched learning experience for all attendees. By participating and attending this event, Continuing Education credit (1 per presentation) can be earned for a maximum of 30 credits.

For more information or to register for the event, click here. Use #LRdrug to follow the conversation!

About LabRoots
LabRoots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.

Media Contact

Lynn Brainard, LabRoots, 714-771-4397, [email protected]

Twitter

SOURCE LabRoots

Related Links

http://www.labroots.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.